Diversified Segmental Defocus Optimization Lenses With and Without Atropine for Myopia Prevention

作者：Yuchang Lu, Xue Yang, Jingwei Zhou, Sitong Chen, Xuewei Li, Yuanqi Deng, Yixuan Zhang, Yan Li, Kai Wang · 发表于：JAMA Ophthalmology · 年份：2025 · DOI：10.1001/jamaophthalmol.2025.2072 · 被引用次数：7 · 研究领域：Ophthalmology and Visual Impairment Studies、Corneal surgery and disorders、Ophthalmology and Eye Disorders

Importance: With growing myopia prevalence worldwide, effective strategies to prevent early-onset myopia are needed. Objective: To evaluate the efficacy of diversified segmental defocus optimization (DSDO) spectacle lenses with or without 0.01% atropine for myopia prevention. Design, Setting, and Participants: This was 1-year randomized placebo-controlled double-masked clinical trial conducted in the Department of Ophthalmology at Peking University People's Hospital from November 2023 to December 2024. Children aged 5 to 12 years with spherical equivalent refraction (SER) of 0.00 to 1.00 diopters (D) after cycloplegia were included, excluding those with ocular diseases, systemic diseases, or previous use of optical or pharmaceutical myopia control methods. Interventions: Participants were randomly assigned in a 1:1:1 ratio to receive DSDO spectacles with placebo eye drops (DSDO group), DSDO spectacles with 0.01% atropine eye drops (DSDOA group), or single-vision spectacles with placebo eye drops (control group). Main Outcomes and Measures: The primary outcomes were the cumulative incidence rate of myopia (defined as SER ≤-0.50 D) and the percentage of participants with fast myopic shift (defined as a spherical equivalent myopic shift ≥0.50 D) over 1 year. Secondary outcomes included changes in SER, axial length, and subfoveal choroidal thickness. Results: Of the 450 children initially randomized (DSDO group: mean [SD] age, 7.05 [0.12] years; 77 [51.3%] male; DSDOA group: mean...